PD-L1 expression is increased in a subset of basal type breast cancer cells.
about
The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune responseA Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All CancersCurrent advances in biomarkers for targeted therapy in triple-negative breast cancerCancer-associated oxidoreductase ERO1-α promotes immune escape through up-regulation of PD-L1 in human breast cancer.Overexpression of MERTK receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity.Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancerNew Immunotherapy Strategies in Breast Cancer.Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells.Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).Prognostic and predictive value of PDL1 expression in breast cancer.PDL1 expression is an independent prognostic factor in localized GIST.Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cellsPDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy.CD4(+) T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8(+) T-cell Targeting of HER2/neu-Expressing CancersAntibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer.Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant SettingRAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint InhibitorsX-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity.PD-L1 Expression Is Associated with Tumor FOXP3(+) Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient.Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types.Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis.PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker.Prioritization schema for immunotherapy clinical trials in glioblastoma.Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunityExpression of Programmed Death Receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast CancerCOX-2 expression positively correlates with PD-L1 expression in human melanoma cells.Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.PD-L1 Expression in Lung Cancer.Mechanism of immune evasion in breast cancer.Role of inflammatory infiltrates in triple negative breast cancer.Therapies for triple negative breast cancer.Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity.Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1.Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N.Biology and Management of Patients With Triple-Negative Breast Cancer.T helper responses are maintained by basal-like breast cancer cells and confer to immune modulation via upregulation of PD-1 ligands.Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome.Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF-β and miR23a transfer.
P2860
Q26766066-A248A8D9-C005-4AA8-B86A-E324303C11A7Q26777111-57F2F5B7-5709-4F13-BF74-DA19838C372DQ28074202-C3CA35EF-1BC6-4934-8F03-61F7FF131857Q33648621-E7B02E09-9ED4-44F2-B162-DB3AA6C608A5Q34170756-253EDC51-010F-420C-9489-6E73107A387CQ34270064-0200AF1A-551C-4C4F-B518-940198AF8038Q34549227-9B9DAD8C-07FB-4C6E-8E33-E283ED87AE22Q35159355-53D6E37A-2C48-43AD-AFC8-5B35404AC4B4Q35182037-72E2882C-B9EC-41AD-8D6E-15BE1AB84702Q35741710-C1838609-7C91-4859-9428-CB9038A7C887Q35798839-985313B3-B34F-4A75-97D6-908AF9892B37Q35922960-18F95578-E05A-44F7-813A-6EC146BED9BDQ35955369-44774195-3A17-49D7-9EE1-3A4F1CD303BFQ36015421-36A62CED-8D8E-4459-BD1A-C28C67C0F7F9Q36539682-848229E6-3D70-495D-ACDF-99C276B4FFF1Q36545353-82C3DED3-00A0-4CA3-882A-546D06D8FB66Q36673469-E4A7E9D0-6F30-4738-8BD8-3750490E368DQ36693087-C79255D6-E7E7-4422-87B5-A218807DBE93Q36751784-23053ACB-11DC-4951-B272-A33CD64106DDQ36882550-C84BD560-74DE-4F8B-AE04-E983B9A5537FQ36939402-769EA6EE-6BC1-49DB-898C-336C62C36CA6Q36963025-632A6476-A7D2-4F81-BB28-2486A83310D3Q37026725-9206476A-0F7B-4A48-ADC2-EC38592D9F72Q37078999-73039827-DD77-4BE5-A8C3-81CC51B96256Q37313139-8A7407E4-067B-4EB8-87E8-A1599979595AQ37316596-E302FEA7-F310-4BEA-8144-D67DF9222C70Q37663388-8438C9FF-22E6-49FA-8C7F-6CFA2B4715C8Q37691082-DAB2FF3F-604B-4BDA-A014-99C51327E6CDQ37704352-7AAE5844-E850-4855-AAF8-D2C6C3251AC3Q37712385-163CFACC-D57D-4DC8-B996-AA64125090A3Q38370266-E4078CA6-B929-4C0B-9D9E-9AD5A3BCDF64Q38424397-450FDE35-EF9F-49EE-9EC8-5D0079A5FEC5Q38451287-9BF704AC-8781-4513-951B-B36DB2C4A4BAQ38629357-CDB3D036-FFDE-4B9A-B7EA-FD01F5AF9833Q38866102-5909DFE6-5E12-4F58-95F5-E01CE371512DQ38893074-B85BA3C2-2B84-4187-AAB1-0E569CAD5EBCQ38996151-8D12BA3D-9FF1-4462-945E-23BDC62BCC7DQ39375196-ECD3E02C-23B3-44A8-BEE4-099C3CF6E577Q40296843-4EBA3ADB-FDF7-41B0-B9D3-FD4D31E4A28AQ40437768-73143DA0-CDD7-43CC-86C5-6B5E8A64F406
P2860
PD-L1 expression is increased in a subset of basal type breast cancer cells.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
PD-L1 expression is increased in a subset of basal type breast cancer cells.
@ast
PD-L1 expression is increased in a subset of basal type breast cancer cells.
@en
type
label
PD-L1 expression is increased in a subset of basal type breast cancer cells.
@ast
PD-L1 expression is increased in a subset of basal type breast cancer cells.
@en
prefLabel
PD-L1 expression is increased in a subset of basal type breast cancer cells.
@ast
PD-L1 expression is increased in a subset of basal type breast cancer cells.
@en
P2093
P2860
P1433
P1476
PD-L1 expression is increased in a subset of basal type breast cancer cells.
@en
P2093
Farah Khalil
Hatem Soliman
Scott Antonia
P2860
P304
P356
10.1371/JOURNAL.PONE.0088557
P407
P577
2014-02-14T00:00:00Z